Conjugates comprising ocular angiogenesis growth factor aptamers and uses thereof in the detection and treatment of ophthalmological angiogenesis indications
AssigneesYissum Research Development Company of the Hebrew University of Jerusalem, Bar-Ilan University
InventorsItamar Willner, Sharon Etery, Yossi Mandel, Amos Markus, Asaf Shoval
Life of this patent
Estimating the term…
Abstract
Provided is an antiangiogenic agent in the form of a vehicle, e.g., a nanoparticle associated (directly or indirectly) with at least one ocular angiogenesis growth factor aptamer, wherein said association labile to interaction between the aptamer and an ocular angiogenesis growth factor.
Claims10
A method of treating an ophthalmic disease or disorder associated with ocular angiogenesis in a subject, selected from macular degeneration, age related macular degeneration, wet macular degeneration, dry macular degeneration and diabetic retinopathy, the method comprising:
- topically administering to an eye of a subject having said ophthalmic disease or disorder an antiangiogenic agent
- comprising a carbon quantum dot (C-dot) having a plurality of nucleic acids associated therewith, each nucleic acid in said plurality of nucleic acids having a sequence comprising at least 9 nucleic acid bases hybridized to at least 9 nucleic acid bases of a complementary nucleic acid sequence comprised within a sequence of at least one ocular angiogenesis growth factor (OAGF) aptamer,
- wherein said antiangiogenic agent penetrates the eye cornea and said hybridization dissociates upon binding of at least one ocular angiogenesis growth factor in the eye to said at least one aptamer.
Dependencies are inferred from the claim text.